Notícias e Atividades da Elevation Oncology

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Elevation Oncology

• Joseph Ferra, Chief Executive Officer and Director
• Michael Carruthers, Director
• Tim Clackson, Director

Recentes movimentos de executivos em Elevation Oncology

• David Dornan, Chief Scientific Officer, deixou a Companhia  (Notícia publicada em 20 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Elevation Oncology.

Elevation Oncology possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Elevation Oncology

• Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
• Elevation Oncology | News Releases
• Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
• Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
• Elevation Oncology | News Releases
• Elevation Oncology | News Releases
• Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
• Elevation Oncology | News Releases
• Elevation Oncology | News Releases
• View more press releases Close

Redes sociais sobre Elevation Oncology

• Elevation Oncology na Wikipedia, Google News e Yahoo Finance
• Elevation Oncology na LinkedIn, Twitter e YouTube